research Off-Label Use of Topical Minoxidil in Alopecia: A Review
Minoxidil helps treat eyebrow thinning, monilethrix, early hair loss, and shortens chemo-related hair loss.
Search
for
Sort by
Research
390-420 / 1000+ results 
research Promising Alternative Clinical Uses of Prostaglandin F2α Analogs: Beyond the Eyelashes
Prostaglandin F2α analogs show promise for treating certain types of hair loss but need more research for other skin conditions.
research Alopecia in Association with Malignancy: A Review
Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.
research Off-Label Uses of Topical Vitamin D in Dermatology: A Systematic Review
Topical vitamin D is useful for some skin conditions but not effective for others, and more research is needed.
research Hair Loss in Systemic Disease
Systemic diseases can cause hair loss, which is often reversible with treatment.
research Medical Treatment of Hepatocellular Carcinoma: Any Progress?
As of 1994, treatments for liver cancer had not significantly improved patient survival.
research Hair Follicles and Their Role in Skin Health
Hair follicles are essential for skin health, aiding in hair growth, wound healing, and immune function.
research Alopecia in General Medicine
The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.
research Diseases on Hair Follicles Leading to Hair Loss Part I: Nonscarring Alopecias
Common types of non-scarring hair loss have various causes and treatments, but more effective solutions are needed.
research The Evolution of Primary Multimodality Treatment in Resectable Breast Cancer
Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.
research Trichodysplasia Spinulosa: Rare Presentation of Polyomavirus Infection in Immunocompromised Patients
Antiviral medication valganciclovir may improve skin and hair in Trichodysplasia Spinulosa patients.
research Epidermal Growth Factor, Innovation and Safety
Recombinant human epidermal growth factor is versatile, effective, and safe for long-term skin and mucosal treatments.
research QR678 and QR678 Neo Hair Growth Formulations: A Cellular Toxicity and Animal Efficacy Study
QR 678 and QR 678 Neo are safe and promote hair growth, potentially helping chemotherapy-induced hair loss.
research Alopecia and Hair Damage Induced by Oncological Therapy
Cancer treatments often cause hair loss and damage, affecting patients' mental health.
research Virilizing Ovarian Tumor in a Woman with an Adrenal Nodule
A woman with high testosterone and an adrenal nodule had an ovarian tumor causing her symptoms, which improved after the tumor was removed.
research Prostate Cancer Update: 2007
2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
research Small Cell Lung Cancer: Results of a Phase II Study of 1,2,4-Triglycidylurazol
The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
research Dermatologic Conditions of the Early Post-Transplant Period in Hematopoietic Stem Cell Transplant Recipients
Skin problems are common after stem cell transplants, and early treatment by dermatologists can improve patient outcomes.
research Hair Diseases: A Big Problem on a Small Surface
Many hair diseases, including those caused by medications and psychological issues, can lead to hair loss and require proper treatment and specialist care.
research Scalp Cooling in the Prevention of Anthracycline-Induced Alopecia
Scalp cooling prevented hair loss in half of the patients, despite significant side effects.
research ER71/ETV2 Promotes Hair Regeneration from Chemotherapy-Induced Hair Loss by Enhancing Angiogenesis
The protein ER71/ETV2 helps regrow hair after chemotherapy by improving the growth of new blood vessels.
research Supportive Oncodermatology: Addressing Dermatologic Adverse Events Associated with Oncologic Therapies
Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.
research Case 18-2018: A 45-Year-Old Woman with Hypertension, Fatigue, and Altered Mental Status
A woman with Cushing's syndrome improved after surgery to remove a tumor causing the condition.
research Nonscarring Hair Loss Disorders
Most types of hair loss can regrow naturally, but there are no effective cures for male pattern or age-related hair loss, and only limited options for females.
research Conceptual Basis for Use of Chemotherapeutic Agents and Their Pharmacology
The conclusion is that effective cancer treatment often requires a combination of therapies, but must be carefully managed due to serious side effects and the risk of immunosuppression.
research Albendazole-Induced Anagen Effluvium: A Brief Literature Review and Our Own Experience
The drug Albendazole, used for treating parasites, can cause sudden hair loss.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research Bimatoprost Solution 0.03% Topical Application to the Eyelid Margin for the Treatment of Eyelash Hypotrichosis
Bimatoprost solution 0.03% is effective for treating sparse eyelashes.
research Evaluation and Management of the Hair Loss Patient in the Primary Care Setting
Doctors should diagnose hair loss by examining the patient and possibly doing tests, and then treat it based on the type, which may prevent permanent hair loss.
research Bexxar, Iodine I 131 Tositumomab, Effective in Long-Term Follow-Up of Non-Hodgkin's Lymphoma
Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.